DCLK2

DCLK2 is a dual-domain serine/threonine kinase that couples microtubule regulation with nuclear signaling to control neuronal development, transcriptional programs, and oncogenic pathways. Its N-terminal doublecortin-like domain binds and stabilizes microtubules independently of its C-terminal CaMKI/IV-related kinase domain, and autophosphorylation acts as a switch that reduces microtubule affinity to enable reversible cytoskeletal control (PMID:15611072). DCLK2 functions redundantly with DCX in hippocampal lamination and pyramidal neuron maturation, as Dcx;Dclk2 double-knockout mice exhibit seizures, interneuron loss, and reduced inhibitory synaptic tone (PMID:19342486). In cancer, DCLK2 directly phosphorylates TBK1 at Ser172 to activate TBK1-mTORC1 signaling and drive tumorigenesis in clear cell renal cell carcinoma, an interaction counteracted by BBOX1 (PMID:38211588, PMID:39934163), and it phosphorylates the transcription factor Ehf to promote its nuclear export and trigger neuronal pyroptosis during chronic cerebral ischemia (PMID:38513137).

1. 2004 High

   Establishing that DCLK2 possesses two functionally independent domains — a microtubule-binding doublecortin domain and a kinase domain — resolved how a single protein can separately regulate cytoskeletal stability and phosphorylation-based signaling, with autophosphorylation serving as a reversible switch between these activities.

   Evidence Domain-deletion constructs, in vitro MT binding and cold-depolymerization assays, autophosphorylation assays, and neuronal immunolocalization

   PMID:15611072

   Open questions at the time

   • Identity of kinases or phosphatases that regulate DCLK2 autophosphorylation in vivo unknown
   • Structural basis for how autophosphorylation reduces MT affinity not resolved
   • Whether both domains function simultaneously in physiological contexts not tested
2. 2006 High

   Despite its CaMK-related kinase domain, DCLK2 does not activate CREB but instead inhibits CRE-dependent transcription through TORC2 phosphorylation, establishing a previously unrecognized divergent transcriptional output for this kinase family member.

   Evidence CRE-reporter assays, CREB Ser133 phosphorylation assays, and TORC2-dependent mechanism dissection in neurons

   PMID:16684769

   Open questions at the time

   • Direct phosphorylation sites on TORC2 by DCLK2 not mapped
   • Physiological contexts requiring DCLK2-mediated CRE inhibition not identified
   • No in vivo confirmation of TORC2 as the relevant mediator
3. 2008 Medium

   Characterization of Dclk2 developmental expression showed it is present in both progenitors and postmitotic neurons, and is not compensatorily upregulated in Dcx knockouts, setting the stage for understanding their genetic redundancy.

   Evidence Northern blot, in situ hybridization, and immunostaining in wild-type and Dcx-knockout mouse brain

   PMID:18075264

   Open questions at the time

   • Post-translational compensation between DCX and DCLK2 not assessed
   • Functional significance of alternative Dclk2 transcripts not determined
4. 2009 High

   Dcx;Dclk2 double-knockout mice revealed that the two genes act redundantly for hippocampal lamination, pyramidal neuron dendritic maturation, and maintenance of inhibitory synaptic tone, explaining why single Dcx knockouts show mild phenotypes.

   Evidence Double-knockout mouse with seizure monitoring, immunohistochemistry, electrophysiology, and c-fos analysis

   PMID:19342486

   Open questions at the time

   • Whether DCLK2's kinase activity or its MT-binding domain mediates the neurodevelopmental phenotype is unknown
   • Contribution of DCLK2 independent of DCX in single-knockout has not been defined with cell-type specificity
5. 2014 Medium

   Discovery that DCLK2 undergoes proteolytic cleavage releasing a kinase fragment that translocates to the nucleus under osmotic stress and phosphorylates JDP2 revealed a stimulus-responsive nuclear signaling function distinct from its cytoplasmic cytoskeletal role.

   Evidence Proteolytic cleavage analysis, subcellular fractionation and live imaging under hyperosmotic stress, yeast two-hybrid screen, in vitro kinase assay in zebrafish

   PMID:24582561

   Open questions at the time

   • Protease responsible for DCLK2 cleavage not identified
   • Functional consequence of JDP2 phosphorylation on downstream gene expression not established
   • Findings from zebrafish ortholog await confirmation in mammalian systems
6. 2022 Medium

   Placing DCLK2 downstream of TCF4/β-catenin signaling and showing it drives EMT and metastasis in breast cancer extended its oncogenic functions beyond kinase-substrate relationships to transcriptional regulation of invasion programs.

   Evidence Lentiviral overexpression/knockdown, Transwell assays, tail-vein lung metastasis model, TCF4/β-catenin inhibitor LF3

   PMID:36477947

   Open questions at the time

   • Direct DCLK2 substrates mediating EMT not identified
   • Mechanism by which DCLK2 promotes invasion without affecting proliferation unclear
   • Single study without independent replication
7. 2024 High

   Identification of TBK1 Ser172 as a direct DCLK2 substrate in ccRCC established the first well-defined oncogenic kinase-substrate axis for DCLK2, linking it to mTORC1 activation and tumorigenesis, subsequently validated by the discovery that BBOX1 suppresses this pathway by disrupting the DCLK2-TBK1 interaction.

   Evidence Kinome-wide siRNA screen, Co-IP, in vitro kinase assay, Ser172 mutagenesis, orthotopic xenografts (PMID:38211588); BBOX1 restoration, Co-IP disruption, xenograft validation (PMID:39934163)

   PMID:38211588 PMID:39934163

   Open questions at the time

   • Whether DCLK2-TBK1 signaling operates in cancers beyond ccRCC not tested
   • Structural basis for BBOX1-mediated disruption of the DCLK2-TBK1 interaction unknown
   • Contribution of the short DCLK2203 isoform versus full-length to normal kidney physiology not addressed
8. 2024 Medium

   Demonstrating that DCLK2 phosphorylates Ehf to promote its nuclear export and derepress Caspase1/3 promoters linked DCLK2 kinase activity to pyroptotic cell death in chronic cerebral ischemia, revealing a non-developmental, pathological neuronal function.

   Evidence In vitro kinase assay for Ehf, subcellular fractionation, promoter assays, OGD-treated HT22 cells and CCI mouse model

   PMID:38513137

   Open questions at the time

   • Specific Ehf phosphorylation sites targeted by DCLK2 not mapped
   • Whether this pyroptosis pathway is active outside ischemia models not explored
   • Single-lab finding awaiting independent validation

• Key unresolved questions include the structural basis for DCLK2's dual-domain architecture, whether its kinase and MT-binding functions are coordinately deployed in neurons, the identity of the protease cleaving DCLK2, and whether its diverse substrate repertoire (TBK1, Ehf, JDP2, TORC2, BAF) reflects context-specific isoform usage or localization-dependent substrate access.
• No crystal or cryo-EM structure of DCLK2 available
• Isoform-specific functions largely uncharacterized
• Integration of MT-binding and kinase functions in a single physiological context not demonstrated